Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Angiotensin-converting Enzyme Inhibitor Clear all
Completed Not applicable Interventional Results available

Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children

NCT00848250
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Angiotensin Converting Enzyme Inhibitor, No ACE Inhibitor
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 3 Interventional Results available

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

NCT01137474
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo-matching dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
164
States / cities
Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019

NCT04338009
View directory record Official record
Conditions
COVID-19
Interventions
Discontinuation of ARB/ACEI, Continuation of ARB/ACEI
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 1 Interventional

The Use of ACE Inhibitors in the Early Renal Post-transplant Period

NCT00270153
View directory record Official record
Conditions
Renal Transplant
Interventions
enalapril, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs

NCT02624050
View directory record Official record
Conditions
Hypotension, Anesthesia
Interventions
Methohexital, Propofol
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jun 11, 2026, 4:22 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease

NCT01101269
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ACEI or ARB, Lisinopril
Drug
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

NCT01669434
View directory record Official record
Conditions
Hypotension on Induction
Interventions
ACEI continuation, ACEI omission
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 90 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 2 Interventional

Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation

NCT00005928
View directory record Official record
Conditions
Atherosclerosis, Coronary Disease, Vasculitis
Interventions
Ramipril
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jun 11, 2026, 4:22 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

NCT01343823
View directory record Official record
Conditions
ACE Inhibitor Induced Angioedema
Interventions
ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg, placebo, placebo match for 30 mg ecallantide arm, placebo match for 10 mg ecallantide arm
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
39
States / cities
Montgomery, Alabama • Colton, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 11, 2026, 4:22 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans

NCT03179163
View directory record Official record
Conditions
Hypertension,Essential
Interventions
Captopril Pill, Enalapril Pill, Hydrochlorothiazide
Drug
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jun 11, 2026, 4:22 AM EDT
Withdrawn Not applicable Interventional

ACEi ARB Withdrawal in CKD Patients

NCT03957161
View directory record Official record
Conditions
Chronic Kidney Disease, Blood Pressure, Angiotensin-converting Enzyme Inhibitor, Angiotensin Receptor Blockers
Interventions
Continuation of ACEi and/or ARBs
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 4 Interventional

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

NCT00185120
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
20
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2012 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Cardiomyopathy in DMD: Lisinopril vs. Losartan

NCT01982695
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD), Cardiomyopathy
Interventions
Losartan, Lisinopril
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Davis, California • Kansas City, Kansas • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Jun 11, 2026, 4:22 AM EDT
Recruiting Early Phase 1 Interventional

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

NCT05530655
View directory record Official record
Conditions
Prostate Cancer, Radiation Toxicity, Urinary Complication
Interventions
Lisinopril Tablets
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 11, 2026, 4:22 AM EDT
Completed No phase listed Observational

A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients

NCT07376265
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes

NCT00403481
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Birmingham, Alabama • Mesa, Arizona • Searcy, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Jun 11, 2026, 4:22 AM EDT
Completed No phase listed Observational

A Cohort Study to Compare the Hospitalization Between Naive Sacubitril/Valsartan and Naive ACEi/ARBs Heart Failure Patients With Reduced Ejection Fraction Using Secondary US Electronic Health Records Data

NCT05096143
View directory record Official record
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEi/ARB
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
42,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Jun 11, 2026, 4:22 AM EDT
Completed No phase listed Observational

Guideline Directed Medical Therapy in Patients With Heart Failure

NCT06700213
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Not applicable Interventional

RAAS Optimization for Acute CHF Patients

NCT03695120
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Change of treatment plan
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

Angiotensin II in General Anesthesia

NCT03733145
View directory record Official record
Conditions
Hypertension
Interventions
Angiotensin II
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jun 11, 2026, 4:22 AM EDT
Completed Phase 4 Interventional Results available

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

NCT00666848
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension
Interventions
Placebo, Enalapril 5mg, Enalapril 10mg, Sitagliptin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Jun 11, 2026, 4:22 AM EDT